SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jesspro who wrote (4327)6/30/2016 9:01:14 AM
From: glass 0.5 full  Read Replies (1) of 4474
 
I will be interested to hear.

My recollection was that pona was not only active across the blood/brain barrier, but was actually present at greater concentrations than in the body generally.

Both of the patients in that article had been on pona prior to the FDA halt and then switched to dasatinib. It was during their dasatinib treatment that the CNS problems occurred.

This appears to be a clear win for pona over dasatinib, esp given the growing understanding that dasatinib and nilotinib both appear to have worse risk profiles than were generally assumed prior to pona's blow-up.

PDF link: google.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News